Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06546449 · ClinicalTrials.gov registry record · Phase 1

LH-001 vs Placebo in Healthy Participants

A Phase 1 study of Healthy, sponsored by Chien-Liang Lin.

Recruiting
Registry status
Phase 1
Development phase
56
Enrollment target
1
Study location

NCT06546449: Recruiting Phase 1 study of Healthy, sponsored by Chien-Liang Lin.

NCT06546449 is a Phase 1 study of Healthy that is actively recruiting participants, run by Chien-Liang Lin. The registered enrollment target is 56 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06546449, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Chien-Liang Lin.

RECRUITING
Registry status
Phase 1
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical trial is to evaluate the safety and tolerability of LH-001 when administered as an oral, single or multiple dose(s) at ascending dose levels in healthy participants.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG LH-001

Study Locations (1)

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2025-05-05
Est. Completion 2027-12
Phase Phase 1

Sponsor

Chien-Liang Lin

1 total trials

What the Registry Record Tells You About NCT06546449

The ClinicalTrials.gov registry entry for NCT06546449 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The listed sponsor is Chien-Liang Lin, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06546449 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT06546449 about?

NCT06546449 is a clinical study titled "LH-001 vs Placebo in Healthy Participants". The purpose of this clinical trial is to evaluate the safety and tolerability of LH-001 when administered as an oral, single or multiple dose(s) at ascending dose levels in healthy participants.

What is the current status of trial NCT06546449?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2025-05-05. Estimated completion is 2027-12.

What conditions does trial NCT06546449 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06546449?

The interventions under investigation include: Placebo (DRUG), LH-001 (DRUG).

Who is sponsoring clinical trial NCT06546449?

This trial is sponsored by Chien-Liang Lin, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06546449 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.